pharmaphorum

OCTOBER 12, 2021

A data-mining study conducted by researchers in the US has found that an already-approved diuretic drug could have potential as a treatment for some patients with Alzheimer’s disease. The results are strong enough to back a proof-of-concept study in people with genetic risk of Alzheimer’s according to the researchers.

Gene Expression 111

Gene Expression Drugs FDA Approval Gene 111

Pharmaceutical Technology

NOVEMBER 29, 2022

PharmaTher also has an agreement in place with Case Western Reserve University to develop ketamine as a treatment for Rett syndrome, a rare genetic neurological disorder. Since ketamine is a generic drug, it is not lucrative to study for pharmaceutical companies, he adds. PharmaTher is not the only player in this space.

Research 275

Research Trials Drugs Generic Drugs 275

Drug Patent Watch

DECEMBER 9, 2024

.” Companies employ various strategies to extend their patent protection, such as: Filing multiple patents for different aspects of a drug Developing new formulations or delivery methods Finding new uses for existing drugs However, these strategies can be controversial, as they may delay the entry of generic drugs into the market.

Medicine 97

Medicine Drugs Production Development 97

XTalks

JANUARY 20, 2025

Blockbuster products like Botox (botulinum toxin) and Restasis (cyclosporine) provided Actavis with high-margin, branded revenue streams that complemented its existing generic drug business. Key drivers of the acquisition included Allergans robust product portfolio, particularly in ophthalmology, neuroscience and aesthetics.

Marketing 104

Marketing Botox Life Science Pharma Companies 104

Cloudbyz

MARCH 5, 2024

Additionally, the complexity of biologics makes them harder to replicate, which means that biosimilars (the biologic equivalent of generic drugs) are less of a competitive threat in the immediate aftermath of patent expiration. Such support can reduce the time and cost associated with bringing a new biologic to market.

Development 97

Development Drugs Immune Response Manufacturing 97

World of DTC Marketing

JANUARY 31, 2021

So where to start… Congresswoman Porter may want to look at the percentage of generic drugs available virus branded (89%). Ex vivo (where cells are genetically modified outside the body) cell and gene therapies have generated considerable excitement on their potential to cure previously incurable diseases.

In-Vivo 187

In-Vivo Generic Drugs Drugs Gene Therapy 187

XTalks

FEBRUARY 5, 2024

million the drug made during the same time in 2022. Alimta was shielded by exclusivity in the US until 2022, after which it faced fierce competition from generic drugs. Price of Yescarta: Yescarta costs approximately $373,000 per treatment regimen. For the first three quarters of 2023, worldwide Alimta revenue was $172.6

FDA Approval 101

FDA Approval Drugs Sales Development 101